Skip to main content

Global Immuno-Oncology Market to Grow at 21% CAGR, Powered by Precision Oncology by 2030

 


The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and prevalence of cancer, advancements in immunotherapy and personalized medicine, favorable regulatory support and approvals, growing investment in cancer immunotherapy R&D, and expanding applications beyond traditional indications are some of the key factors driving the immuno-oncology market.

Immuno-oncology is a rapidly evolving field of cancer treatment that harnesses the body's immune system to recognize, attack, and eliminate cancer cells. Unlike conventional therapies like chemotherapy and radiation, which directly target tumors, immuno-oncology therapies enhance the immune response against cancer. Key approaches include immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, CAR-T cell therapy, bispecific antibodies, and cancer vaccines. These therapies have revolutionized cancer care by offering durable responses and improved survival in various malignancies. Ongoing research focuses on enhancing efficacy, overcoming resistance, and expanding applications to more cancer types through combination strategies and personalized medicine approaches.

Download a free sample report now 👉
https://meditechinsights.com/immuno-oncology-market/request-sample/

Increasing incidence and prevalence of cancer to propel market demand

The rising global incidence and prevalence of cancer are major drivers of the immuno-oncology market. With cancer being a leading cause of death worldwide, the demand for advanced, effective treatments is growing. . According to the WHO In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths, and the cancer cases are expected to increase significantly due to aging populations, lifestyle changes, and environmental factors. And, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated in 2022 The increasing cases of lung, colorectal, breast, and prostate cancers necessitate innovative therapies like immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Additionally, aging populations and lifestyle factors, such as smoking and obesity, contribute to higher cancer rates, further driving market expansion. As a result, pharmaceutical companies are investing heavily in immuno-oncology research to develop novel, targeted therapies that improve patient outcomes and survival rates.

Advancements in Immuno-Oncology Products: Emerging Therapies and Future Opportunities

The immuno-oncology field is advancing rapidly, with recent FDA approvals of bispecific T-cell engagers (BiTEs) and renewed interest in cancer vaccines, particularly mRNA-based therapies. Cell therapies, including CAR-T, are expanding into new indications and earlier treatment lines, such as non-Hodgkin’s lymphoma (NHL). Bispecific antibodies offer a promising approach by combining T-cell redirection with checkpoint modulation, potentially overcoming T-cell exhaustion. Additionally, dual-targeting immune checkpoint inhibitors (ICIs) may enhance efficacy over traditional combinations. Innovations in modifying the tumor microenvironment to counteract resistance present significant opportunities for the immuno-oncology market, driving new therapeutic strategies and improved patient outcomes.

Competitive Landscape Analysis

The global immuno-oncology market is marked by the presence of established and emerging market players such as Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., AstraZeneca, Sanofi, Moderna, Inc., GSK plc, AbbVie Inc., and Merck & Co., Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/immuno-oncology-market/request-sample/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global immuno-oncology market at the regional- and country-level from 2023 to 2030. The report further segments the market based on therapy type, cancer type, end user.

  • Market Size & Forecast (2023-2030), By Therapy Type, USD Million
    • Immune Checkpoint Inhibitors (ICIs)
    • CAR-T Cell Therapy
    • Cancer Vaccines
    • Bispecific Antibodies
    • Monoclonal Antibodies
    • Oncolytic Viruses
    • Cytokine Therapy
    • Others
  • Market Size & Forecast (2023-2030), By Cancer Type, USD Million
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Ovarian Cancer
    • Others
  • Market Size & Forecast (2023-2030), By End User, USD Million
    • Hospitals & Cancer Treatment Centers
    • Specialty Clinics
    • Others
  • Market Size & Forecast (2023-2030), By Region, USD Million
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of Asia Pacific
    • Latin America
    • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more